Technical Analysis for 0AAJ - PolyPeptide Group AG
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Support | Bullish | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| 20 DMA Support | Bullish | -0.32% | |
| Bollinger Band Squeeze | Range Contraction | -0.32% | |
| Narrow Range Bar | Range Contraction | -0.32% | |
| Gapped Down | Weakness | -0.32% | |
| 20 DMA Support | Bullish | -0.66% | |
| Bollinger Band Squeeze | Range Contraction | -0.66% | |
| Crossed Above 20 DMA | Bullish | -0.99% |
| Alert | Time |
|---|---|
| Possible Inside Day | about 17 hours ago |
| Possible NR7 | about 17 hours ago |
| Down 1% | about 20 hours ago |
| 10 DMA Support | about 20 hours ago |
| 20 DMA Support | about 21 hours ago |
Get this analysis on your stocks daily!
PolyPeptide Group AG Description
PolyPeptide Group AG operate as a contract development and manufacturing company in Europe, the Americas, the Asia Pacific, and internationally. It focuses on peptide- and oligonucleotide-based therapies for pharma and biotech customers. The company also develops and manufactures active ingredients for therapies that range from the treatment of metabolic diseases, such as diabetes or obesity, as well as cancer and cardiovascular, or neurological disorders. In addition, it engages in manufacturing custom research grade peptides; and developing neoantigen peptide to support personalized cancer therapies. Further, the company is involved in manufacturing peptides for commercially approved peptide therapeutics. Additionally, it manufactures peptide-based generics for human and veterinary markets; and cosmetic peptides. The company offers regulatory affair support services. It has a collaboration agreement with Numaferm for peptide development and production The company was founded in 1952 and is headquartered in Baar, Switzerland. PolyPeptide Group AG is a subsidiary of Draupnir Holding B.V.
Classification
Keywords: Cancer Diabetes Obesity Cancer Therapies Personalized Cancer
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 30.9 |
| 52 Week Low | 14.1898 |
| Average Volume | 16,485 |
| 200-Day Moving Average | 19.94 |
| 50-Day Moving Average | 23.63 |
| 20-Day Moving Average | 29.15 |
| 10-Day Moving Average | 29.02 |
| Average True Range | 0.98 |
| RSI (14) | 61.98 |
| ADX | 40.53 |
| +DI | 32.28 |
| -DI | 15.73 |
| Chandelier Exit (Long, 3 ATRs) | 27.95 |
| Chandelier Exit (Short, 3 ATRs) | 30.85 |
| Upper Bollinger Bands | 30.38 |
| Lower Bollinger Band | 27.92 |
| Percent B (%b) | 0.52 |
| BandWidth | 8.43 |
| MACD Line | 1.38 |
| MACD Signal Line | 1.76 |
| MACD Histogram | -0.3872 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 30.03 | ||||
| Resistance 3 (R3) | 30.05 | 29.80 | 29.89 | ||
| Resistance 2 (R2) | 29.80 | 29.59 | 29.79 | 29.85 | |
| Resistance 1 (R1) | 29.50 | 29.46 | 29.65 | 29.48 | 29.80 |
| Pivot Point | 29.25 | 29.25 | 29.33 | 29.24 | 29.25 |
| Support 1 (S1) | 28.95 | 29.04 | 29.10 | 28.93 | 28.61 |
| Support 2 (S2) | 28.70 | 28.91 | 28.69 | 28.56 | |
| Support 3 (S3) | 28.40 | 28.70 | 28.52 | ||
| Support 4 (S4) | 28.38 |
